API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Alecensa (alectinib) is an ALK tyrosine kinase receptor inhibitor, which is under phase 3 clinical trials for postoperative adjuvant therapy for ALK fusion gene-positive non-small cell lung cancer.
Lead Product(s): Alectinib Hydrochloride
Therapeutic Area: Oncology Product Name: Alecensa
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2023
Details:
Alecensa (alectinib) is a small molecule and act as ALK inhibitor, which is being investigated in PIII trial for people With ALK-positive early-stage lung cancer.
Lead Product(s): Alectinib Hydrochloride
Therapeutic Area: Oncology Product Name: Alecensa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2023
Details:
Alecensa (alectinib) is a small molecule and act as ALK inhibitor, which is investigating in PIII trial for people With ALK-positive early-stage lung cancer.
Lead Product(s): Alectinib Hydrochloride
Therapeutic Area: Oncology Product Name: Alecensa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Genentech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2023